Although laboratory-generated autologous skin substitute products have existed for decades, their availability has significantly declined over the past 20 years due to stricter regulatory frameworks and insufficient collaboration across Europe. Our mission addresses this critical gap with a multi-faceted approach:
- Boost and secure the implementation of new and existing (hospital) production facilities for autologous skin substitutes
- Support the development of advanced therapy medicinal products (ATMPs) in the preclinical phase
- Promote regulatory clarity and reduce unnecessary barriers
- Train clinical burn teams to ensure optimal use of laboratory-generated autologous skin substitutes
We are working to ensure equal and timely access to autologous skin substitute products for all severely burned patients in Europe. Some of these therapies have been available and effective for over 40 years. Today, however, regulatory complexity and fragmented efforts are limiting access. By fostering collaboration, harmonization, and training, we aim to improve long-term outcomes and public health.